aResearch Unit, Hospital Universitario Nuestra Señora de Candelaria, Instituto de Investigación Sanitaria de Canarias, Santa Cruz de Tenerife, Spain bGenomics Division, Instituto Tecnológico y de ...

The Europe nutritional supplements market, valued at $27.16 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 6.3% over the forecast period from 2022 to 2032. This ...

The North America nutritional supplements market, valued at $27.16 billion in 2022, is projected to grow at a compound annual growth rate (CAGR) of 5.8%, reaching $88.83 billion by 2032. This growth ...

Do multivitamins ensure your body gets everything it needs? It's a complicated question without a one-size-fits-all answer. While there’s no doubt taking multivitamins may benefit some people ...

ABL Bio Inc., a South Korean biotech company, will license out its proprietary blood-brain barrier shuttle platform, called the Grabody-B, to UK-based pharmaceutical giant GSK plc in a deal expected ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Long-term results from the Women’s Health Initiative have revealed associations between cancers and hormone therapy, supplements, diet, BMI, metabolic syndrome, and NSAIDs.

Millions take them without a second thought, but do daily multivitamins improve your health? Here's what science and your body might say about this daily habit. Listen to Story Multivitamins combine ...

At some point in everyone’s life, they go down the vitamin route – whether because they have a restrictive diet and need additional supplements, have been instructed by their doctor ...

Thorne multivitamins hit all the high points for a high-quality daily supplement. (Thorne) ...

GSK plc GSK announced that it has signed an agreement with Massachusetts-based biopharmaceutical company Boston Pharmaceuticals to acquire the latter’s lead pipeline drug, efimosfermin alfa ...

[LONDON] GSK agreed to buy an experimental medicine to treat liver disease for as much as US$2 billion as the UK drugmaker seeks to shore up its pipeline of new medicines. The treatment developed by ...